Dallas, May 20, 2025 (Globe Newswire) – SpectralAI, Inc. (NASDAQ: MDAI) (“Spectral AI” or “Company”) is a leading developer of AI-driven DeepView® systems. RCSI Connolly Hospital was awarded the best research project at the 2025 Education Awards, using the DeepView system to the Diabetic Foot Ulcer (DFUS) project.
The Education Award recognizes, encourages and celebrates excellence in third-level education across Ireland, including both state-funded and private institutions. The award is part of the BusinessRiver network and brings together over 12,000 senior experts through over 30 award programs across a wide range of industries.
“This project highlights real-time multispectral imaging and AI-driven analysis and innovative integration that guides faster and more effective assessment of diabetic foot ulcers and potential treatment strategies. When working with the DeepView System, the award celebrates outstanding interdisciplinary research efforts that bring together clinical, academic and industry expertise. “This project features the innovative use of AI and imaging for real-time wound assessment and was awarded the best research project to showcase the cutting edge technology of the DeepView system that has improved patient outcomes.”
“This award-winning research from partners at RCSI is a key milestone in examining the clinical value of the DeepView® system,” said Jeremiah Sparks, Chief Commercialization Officer at Spectral AI. “Real-world data generated in Ireland not only helps to expand the clinical evidence base of DeepView, but also helps shape the commercialization strategy. These findings are strongly erected as we prepare to bring DeepView to a wider market.”
About Spectrum AI
Spectral AI, Inc. is a Dallas-based predictive AI company focusing on medical diagnosis for faster, more accurate treatment decisions in wound care, with early uses involving burned patients. The company is working to revolutionize wound care management by using “Unknowns®Seed®” using the DeepView® system. The DeepView® system is being developed as a predictive device that provides clinicians with an objective and immediate assessment of the potential for burn healing prior to treatment or other medical intervention. With its algorithm-driven outcomes and goals to surpass current standards of care in the future, the DeepView® system is expected to provide fast and accurate treatment insights into value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView® system, visit www.spectral-ai.com.
Forward-looking statements
The specific statements made in this release are “future-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. When used in this press release, variations of “estimation”, “projection”, “expectation”, “prediction”, “prediction”, “plan”, “intention”, “believe”, “may”, “will”, “sub”, “sub”, “future”, “suggestion”, and negative expressions of these words or similar expressions are negative versions of a negative word or expression. These forward-looking statements do not guarantee future performance, conditions, or results and contain many known unknown risks, uncertainties, assumptions and other important factors. As such, readers are warned not to undue reliance on forward-looking statements.
Investors should carefully consider the aforementioned factors and other risks and uncertainties listed in the “Risk Factors” section of our filings, including the above factors and other documents filed by the company. These filings identify and address other significant risks and uncertainties that could cause actual events or outcomes, and are materially different from those contained in forward-looking statements.
Please contact us for information on the relationship between the media and investors.
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 toll free – USA and Canada
(404) 281-8556 Mobile and WhatsApp
Email: (Protected Email)
